Genetic Testing in Youth with High Cholesterol

National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk

The 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol reaffirmed that lifestyle changes and statin treatment are therapeutic cornerstones…

Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force

This scientific statement provides a comprehensive review of the current evidence base available from recent systematic reviews and meta-analyses on the effects of low-CHO and…

Effects of Low-Carbohydrate and Very-Low-Carbohydrate Diets (Including Ketogenic) – Cardiometabolic Impact

Enhancing the Value of PCSK9 Monoclonal Antibodies (MAb)

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population.

Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit: A consensus statement from the National Lipid Association

Acquisition costs and cost-effectiveness have limited access and recommendations to use proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting monoclonal antibodies (mAbs).

NLA Recommendations for Patient-Centered Management of Dyslipidemia

The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical…